Skip to main content

Market Overview

Are GNC, Vitamin Shoppe At Risk For A Health Scandal?

Share:

The New York Times reported on Tuesday that the Food and Drug Administration may be ignoring an amphetamine-like substance found in many popular weight-loss and workout supplements.

In December, these products were pulled by Canadian health authorities, who labeled them "a serious health risk," according to the report. Thus far, authorities at the FDA have done nothing to regulate the products.

However, there is a growing uprising from outside groups and even a group of 14 state attorneys general who just last week asked Congress to embolden the FDA with more authority to regulate supplements.

For GNC Holdings Inc (NYSE: GNC), the controversy has sparked the company to agree to "extensive new testing and quality control procedures for its store-brand herbal products." However, should pressure continue to build, it's unlikely that this will be enough.

At Vitamin Shoppe Inc (NYSE: VSI), the New York Times found at least three supplements containing this chemical in stock, with one of them being the specific product banned by Canadian regulators.

After the recent Lumber Liquidators Holdings Inc (NYSE: LL) health-related selloff, it is easy for the question to arise as to whether GNC and Vitamin Shoppe are doing enough. At present, investors may be uncertain.

 

Related Articles (VSI + GNC)

View Comments and Join the Discussion!

Posted-In: lumber liquidators The New York TimesNews Rumors Media

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com